Cochrane · systematic review · CD002219
Ivermectin for onchocercal eye disease (river blindness)
Ejere, HOD, Schwartz, E, Wormald, R, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 35.7%Very low 1 · 7.1%Low 4 · 28.6%Moderate 3 · 21.4%High 1 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyIvermectin to prevent and treat onchocercal eye disease in people infected with O.volvulus
Population: people infected with O.volvulus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual impairment | no estimate extracted | 2 studies · 354 participants | Ungraded |
Visual field loss | no estimate extracted | 0 studies · 0 participants | Ungraded |
Punctate keratitis | no estimate extracted | 0 studies · 2 participants | Ungraded |
Sclerosing keratitis | RR 0.06 [0, 1.23] | 1 study · 39 participants | Low Downgraded: imprecision, indirectness |
Iridocyclitis | no estimate extracted | 0 studies · 2 participants | Ungraded |
Chorioretinitis | RR 0.02 [0, 0.32] | 1 study · 200 participants | Moderate Downgraded: indirectness |
Optic nerve disease | no estimate extracted | 2 studies · 354 participants | Ungraded |
Ivermectin to prevent and treat onchocercal eye disease in people living in communities affected by O.volvulus
Population: people living in communities affected by O.volvulus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual impairment | RR 1.08 [0.33, 3.5] | 1 study · 485 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Visual field loss | RR 0.6 [0.41, 0.89] | 1 study · 636 participants | High |
Punctate keratitis | RR 0.33 [0.22, 0.49] | 1 study · 551 participants | Moderate Downgraded: risk of bias |
Sclerosing keratitis | RR 0.74 [0.52, 1.06] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision |
Iridocyclitis | RR 0.62 [0.43, 0.9] | 1 study · 554 participants | Moderate Downgraded: risk of bias |
Chorioretinitis | RR 1.75 [0.91, 3.37] | 1 study · 528 participants | Low Downgraded: risk of bias, imprecision |
Optic nerve disease | RR 0.78 [0.57, 1.06] | 2 studies · 3577 participants | Low Downgraded: risk of bias, inconsistency |
Ivermectin to prevent and treat onchocercal eye disease in people infected with O.volvulus
Population: people infected with O.volvulus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual impairment | no estimate extracted | 2 studies · 354 participants | Ungraded |
Visual field loss | no estimate extracted | 0 studies · 0 participants | Ungraded |
Punctate keratitis | no estimate extracted | 0 studies · 2 participants | Ungraded |
Sclerosing keratitis | RR 0.06 [0, 1.23] | 1 study · 39 participants | Low Downgraded: imprecision, indirectness |
Iridocyclitis | no estimate extracted | 0 studies · 2 participants | Ungraded |
Chorioretinitis | RR 0.02 [0, 0.32] | 1 study · 200 participants | Moderate Downgraded: indirectness |
Optic nerve disease | no estimate extracted | 2 studies · 354 participants | Ungraded |
Ivermectin to prevent and treat onchocercal eye disease in people living in communities affected by O.volvulus
Population: people living in communities affected by O.volvulus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Visual impairment | RR 1.08 [0.33, 3.5] | 1 study · 485 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Visual field loss | RR 0.6 [0.41, 0.89] | 1 study · 636 participants | High |
Punctate keratitis | RR 0.33 [0.22, 0.49] | 1 study · 551 participants | Moderate Downgraded: risk of bias |
Sclerosing keratitis | RR 0.74 [0.52, 1.06] | 1 study · 560 participants | Low Downgraded: risk of bias, imprecision |
Iridocyclitis | RR 0.62 [0.43, 0.9] | 1 study · 554 participants | Moderate Downgraded: risk of bias |
Chorioretinitis | RR 1.75 [0.91, 3.37] | 1 study · 528 participants | Low Downgraded: risk of bias, imprecision |
Optic nerve disease | RR 0.78 [0.57, 1.06] | 2 studies · 3577 participants | Low Downgraded: risk of bias, inconsistency |